What is the maximum daily dose of hydralazine for a patient with end-stage renal disease (ESRD) undergoing dialysis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Maximum Daily Dose of Hydralazine for Dialysis Patients

The maximum daily dose of hydralazine for a dialysis patient is 300 mg per day in divided doses, which is the same as for patients without renal disease, as hydralazine does not require dose adjustment in end-stage renal disease (ESRD). 1, 2

Standard Dosing Guidelines

  • The FDA-approved maximum dose is 300 mg daily in divided doses for all patients, including those with ESRD 2
  • The ACC/AHA Heart Failure Guidelines specify hydralazine dosing as 25-50 mg three or four times daily initially, with a maximum of 300 mg daily in divided doses 1
  • No dose reduction is required for renal insufficiency or dialysis patients 1

Practical Dosing Strategy

  • Start with 10 mg four times daily for 2-4 days, then increase to 25 mg four times daily for the first week 2
  • For the second week onward, increase to 50 mg four times daily as tolerated 2
  • The typical maintenance dose ranges from 100-200 mg daily in divided doses, though up to 300 mg daily may be needed in resistant cases 2
  • Hydralazine should be given 3-4 times daily due to its short duration of action 1, 2

Special Considerations for Dialysis Patients

  • Timing relative to dialysis sessions is not clinically relevant, as hydralazine is not significantly removed by hemodialysis 3
  • A pilot trial in maintenance hemodialysis patients successfully titrated combination hydralazine/isosorbide dinitrate to 75 mg hydralazine three times daily (225 mg total daily) with good tolerability 3
  • Intradialytic hypotension may actually be less frequent with hydralazine therapy (0.47 events/patient-year with hydralazine vs 1.83 events/patient-year with placebo) 3

Important Safety Warnings

  • The incidence of drug-induced lupus syndrome and ANCA-associated vasculitis is dose-dependent and increases significantly at doses above 200 mg daily 2, 4
  • Hydralazine can cause severe acute kidney injury and ANCA-positive crescentic glomerulonephritis, even in patients already on dialysis 4
  • Monitor for lupus-like symptoms (arthralgias, fever, rash) and consider checking ANA and ANCA antibodies if symptoms develop, particularly at higher doses 4
  • Common side effects include headache, nausea, and diarrhea, which occur more frequently than with placebo 3

Monitoring Recommendations

  • Blood pressure should be monitored closely during dose titration, particularly for symptomatic hypotension 3
  • Given the increased risk of drug-induced lupus at doses >200 mg daily, consider combination therapy with other antihypertensives rather than pushing hydralazine to maximum doses 2
  • The combination of hydralazine with a thiazide diuretic and/or beta blocker allows for lower hydralazine doses while maintaining efficacy 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.